Shares of ImmunityBio (NASDAQ:IBRX) climbed 6% on Wednesday morning after the company said Saudi Arabia’s Food and Drug ...

If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...

Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...

Trethera Corp. received a $2.7M NIH grant to study combining TRE-515 with KRAS inhibitors for lung cancer. Learn how this study targets drug resistance.

Please provide your email address to receive an email when new articles are posted on . Guidelines for the management of early-stage non-small cell lung cancer were last published in 2013. The new ...

A new report from the American Cancer Association predicts lung cancer will cause more deaths than any other in 2026.